The coronavirus vaccines developed in the U.S., Germany, and the U.K. are in wide use globally. But they are far from the only ones being deployed, especially in the developing world. China, in particular, has displayed intense focus on what is now being called “vaccine diplomacy,” pledging 500 million doses to 45 countries. The vast majority of these are manufactured by China’s Sinovac and Sinopharm — companies (the former state-owned) that leaped into the vaccine development race earlier than many outside of China. The trouble is, both of these companies have yet to publish the data from many of their trials, relying instead on self-reported efficacy numbers. We spoke with Emily de La Bruyère, of the Foundation for Defense of Democracies, to discuss what this lack of transparency means within the larger context of China’s vaccine effort — and why it might be troubling news for the rest of the world.